{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T09:06:55Z","timestamp":1789204015999,"version":"build-2803163510"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Indian Journal of Medical Microbiology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ijmmb.2026.101203","type":"journal-article","created":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T06:42:16Z","timestamp":1783147336000},"page":"101203","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Rising threats of ceftolozane-tazobactam resistance in P. aeruginosa and A. baumannii: Species-, phenotype-, and geography-specific insights from a systematic review and meta-analysis"],"prefix":"10.1016","volume":"63","author":[{"given":"Hongda","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weidong","family":"Qiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqiang","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijmmb.2026.101203_bib1","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1089\/mdr.2015.0220","article-title":"Multidrug-resistant gram-negative bacterial infections in the hospital setting: overview, implications for clinical practice, and emerging treatment options","volume":"22","author":"Cerceo","year":"2016","journal-title":"Microb Drug Resist"},{"key":"10.1016\/j.ijmmb.2026.101203_bib2","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3390\/pathogens10030373","article-title":"Acinetobacter baumannii antibiotic resistance mechanisms","volume":"10","author":"Kyriakidis","year":"2021","journal-title":"Pathogens"},{"key":"10.1016\/j.ijmmb.2026.101203_bib3","doi-asserted-by":"crossref","first-page":"935","DOI":"10.3390\/microorganisms8060935","article-title":"Antibiotic resistance profiles, molecular mechanisms and innovative treatment strategies of Acinetobacter baumannii","volume":"8","author":"Vrancianu","year":"2020","journal-title":"Microorganisms"},{"key":"10.1016\/j.ijmmb.2026.101203_bib4","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1128\/CMR.00115-20","article-title":"New \u03b2-lactam\u2013\u03b2-lactamase inhibitor combinations","volume":"34","author":"Yahav","year":"2020","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijmmb.2026.101203_bib5","doi-asserted-by":"crossref","first-page":"5681","DOI":"10.2147\/IDR.S338827","article-title":"New \u03b2-lactam antibiotics and ceragenins\u2013a study to assess their potential in treatment of infections caused by multidrug-resistant strains of Pseudomonas aeruginosa","author":"Paprocka","year":"2021","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.ijmmb.2026.101203_bib6","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1128\/AAC.01970-17","article-title":"Activity of ceftolozane-tazobactam against carbapenem-resistant, non-carbapenemase-producing Pseudomonas aeruginosa and associated resistance mechanisms","volume":"62","author":"Wi","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijmmb.2026.101203_bib7","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1128\/CMR.00031-19","article-title":"Epidemiology and treatment of multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa infections","volume":"32","author":"Horcajada","year":"2019","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijmmb.2026.101203_bib8","volume":"85","year":"2011"},{"key":"10.1016\/j.ijmmb.2026.101203_bib9","series-title":"Breakpoint tables for interpretation of MICs and zone diameters","year":"2020"},{"key":"10.1016\/j.ijmmb.2026.101203_bib12","series-title":"Open Forum infect. Dis.","article-title":"Activity of ceftolozane\/tazobactam in vitro against Gram-negative isolates from pediatric patients: SMART 2017-2021","volume":"10","author":"Mu","year":"1698"},{"key":"10.1016\/j.ijmmb.2026.101203_bib13","series-title":"Open forum infect. Dis.","article-title":"2154. Cross-resistance of ceftolozane-tazobactam and imipenem-relebactam against clinical P. aeruginosa isolates from bloodstream and respiratory tract Infections\u2013SMART United States 2019-2021","volume":"10","author":"Lob","year":"2023"},{"key":"10.1016\/j.ijmmb.2026.101203_bib14","doi-asserted-by":"crossref","first-page":"559","DOI":"10.3855\/jidc.12368","article-title":"Activity of ceftolozane\/tazobactam against commonly encountered antimicrobial resistant Gram-negative bacteria in Lebanon","volume":"14","author":"Araj","year":"2020","journal-title":"J Infect Dev Ctries"},{"key":"10.1016\/j.ijmmb.2026.101203_bib15","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12866-021-02135-z","article-title":"Activity of ceftolozane\/tazobactam against Gram-negative isolates from patients with lower respiratory tract infections\u2013SMART United States 2018\u20132019","volume":"21","author":"Karlowsky","year":"2021","journal-title":"BMC Microbiol"},{"key":"10.1016\/j.ijmmb.2026.101203_bib16","doi-asserted-by":"crossref","DOI":"10.1093\/jacamr\/dlae077","article-title":"Activity of ceftolozane\/tazobactam and imipenem\/relebactam against Gram-negative clinical isolates collected in Mexico\u2014SMART 2017\u20132021","volume":"6","author":"Karlowsky","year":"2024","journal-title":"JAC Antimicrob Resist"},{"key":"10.1016\/j.ijmmb.2026.101203_bib17","doi-asserted-by":"crossref","first-page":"802","DOI":"10.3390\/antibiotics13090802","article-title":"Antibiotic susceptibility of aerobic and facultative anaerobic gram-negative rods in Hong Kong and implications on usefulness of ceftazidime-avibactam and ceftolozane-tazobactam","volume":"13","author":"Teng","year":"2024","journal-title":"Antibiotics"},{"key":"10.1016\/j.ijmmb.2026.101203_bib18","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1093\/jac\/dku184","article-title":"Antimicrobial activity of ceftolozane\/tazobactam tested against Pseudomonas aeruginosa and enterobacteriaceae with various resistance patterns isolated in European hospitals (2011\u201312)","volume":"69","author":"Sader","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijmmb.2026.101203_bib19","first-page":"68","article-title":"Antimicrobial activity of ceftolozane-tazobactam against multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa clinical isolates from a Spanish hospital","volume":"32","author":"L\u00f3pez-Calleja","year":"2019","journal-title":"Rev Espa\u00f1ola Quimioter"},{"key":"10.1016\/j.ijmmb.2026.101203_bib20","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.01697-22","article-title":"Antimicrobial activity of ceftolozane-tazobactam, ceftazidime-avibactam, and cefiderocol against multidrug-resistant Pseudomonas aeruginosa recovered at a German university hospital","volume":"10","author":"Weber","year":"2022","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.ijmmb.2026.101203_bib21","first-page":"203","article-title":"Antimicrobial activity of cephalosporin\u2013beta-lactamase inhibitor combinations against drug-susceptible and drug-resistant Pseudomonas aeruginosa strains","volume":"15","author":"Alnimr","year":"2020","journal-title":"J Taibah Univ Med Sci"},{"key":"10.1016\/j.ijmmb.2026.101203_bib22","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.2147\/IDR.S344165","article-title":"Ceftazidime\/avibactam and other commonly used antibiotics activity against enterobacterales and pseudomonas aeruginosa isolated in Poland in 2015\u20132019","author":"Zalas-Wi\u0119cek","year":"2022","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.ijmmb.2026.101203_bib23","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ijantimicag.2017.09.016","volume":"51","author":"Pfaller","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijmmb.2026.101203_bib24","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/jac\/dkx009","article-title":"Ceftolozane\/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012\u201315)","volume":"72","author":"Pfaller","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijmmb.2026.101203_bib25","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jinf.2014.04.004","article-title":"Ceftolozane\/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012)","volume":"69","author":"Sader","year":"2014","journal-title":"J Infect"},{"key":"10.1016\/j.ijmmb.2026.101203_bib26","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.ijantimicag.2014.01.032","article-title":"Ceftolozane\/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012)","volume":"43","author":"Farrell","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijmmb.2026.101203_bib27","series-title":"Open Forum infect. Dis.","article-title":"Ceftolozane\/tazobactam and imipenem\/relebactam cross-susceptibility among clinical isolates of Pseudomonas aeruginosa from patients with respiratory tract infections in ICU and non-ICU wards\u2014Smart United States 2017\u20132019","volume":"8","author":"Lob","year":"2021"},{"key":"10.1016\/j.ijmmb.2026.101203_bib28","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.diagmicrobio.2018.05.002","article-title":"Ceftolozane\/tazobactam sensitivity patterns in Pseudomonas aeruginosa isolates recovered from sputum of cystic fibrosis patients","volume":"92","author":"Finklea","year":"2018","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijmmb.2026.101203_bib29","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.ijid.2021.09.064","article-title":"Ceftolozane-tazobactam activity against clinical isolates of Pseudomonas aeruginosa from ICU patients with pneumonia: united States, 2015\u20132018","volume":"112","author":"Pfaller","year":"2021","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ijmmb.2026.101203_bib30","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.jgar.2017.05.025","article-title":"Ceftolozane\u2013tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Australia and New Zealand: report from an Antimicrobial Surveillance Program (2013\u20132015)","volume":"10","author":"Pfaller","year":"2017","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.ijmmb.2026.101203_bib31","first-page":"749","article-title":"Ceftolozane-tazobactam, ceftazidime-avibactam and ceftazidime-avibactam plus aztreonam combination: upcoming hope for hospital-acquired MDR\/XDR Pseudomonas aeruginosa infections","volume":"5","author":"Elbrolosy","year":"2024","journal-title":"Microbes and Infectious Diseases"},{"key":"10.1016\/j.ijmmb.2026.101203_bib32","doi-asserted-by":"crossref","first-page":"iv32","DOI":"10.1093\/jac\/dkz285","article-title":"Characterization of carbapenem-resistant and XDR Pseudomonas aeruginosa in Canada: results of the CANWARD 2007\u201316 study","volume":"74","author":"McCracken","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijmmb.2026.101203_bib33","doi-asserted-by":"crossref","DOI":"10.1093\/jacamr\/dlaa129","article-title":"Collective assessment of antimicrobial susceptibility among the most common Gram-negative respiratory pathogens driving therapy in the ICU","volume":"3","author":"Moise","year":"2021","journal-title":"JAC Antimicrob Resist"},{"key":"10.1016\/j.ijmmb.2026.101203_bib34","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s10096-021-04363-7","article-title":"Comparative activity of newer \u03b2-lactam\/\u03b2-lactamase inhibitor combinations against Pseudomonas aeruginosa from patients hospitalized with pneumonia in European medical centers in 2020","volume":"41","author":"Sader","year":"2022","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijmmb.2026.101203_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.diagmicrobio.2019.05.005","article-title":"Comparison of ceftazidime-avibactam and ceftolozane-tazobactam in vitro activities when tested against gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2017\u20132018)","volume":"96","author":"Sader","year":"2020","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijmmb.2026.101203_bib36","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1128\/AAC.46.3.940-940.2002","article-title":"Dicyclic and tricyclic diaminopyrimidine derivatives as potent inhibitors of cryptosporidium parvum dihydrofolate reductase: structure-activity and structure-selectivity correlations","volume":"46","author":"Nelson","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijmmb.2026.101203_bib37","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1007\/s10096-021-04308-0","article-title":"The ERACE-PA global surveillance program: ceftolozane\/tazobactam and ceftazidime\/avibactam in vitro activity against a global collection of carbapenem-resistant Pseudomonas aeruginosa","volume":"40","author":"Gill","year":"2021","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijmmb.2026.101203_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.diagmicrobio.2019.114925","article-title":"In vitro activity of ceftolozane\/tazobactam against phenotypically defined extended-spectrum \u03b2-lactamase (ESBL)-positive isolates of Escherichia coli and Klebsiella pneumoniae isolated from hospitalized patients (SMART 2016)","volume":"96","author":"Karlowsky","year":"2020","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijmmb.2026.101203_bib39","doi-asserted-by":"crossref","first-page":"5707","DOI":"10.1128\/AAC.01404-13","article-title":"In vitro activity of ceftolozane-tazobactam against Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals in the CANWARD study, 2007 to 2012","volume":"57","author":"Walkty","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijmmb.2026.101203_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.diagmicrobio.2020.115204","article-title":"In vitro activity of ceftolozane-tazobactam and ceftazidime-avibactam against Pseudomonas aeruginosa isolated from patients with cystic fibrosis","volume":"99","author":"Nolan","year":"2021","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijmmb.2026.101203_bib41","doi-asserted-by":"crossref","first-page":"e00920","DOI":"10.1128\/aac.00920-23","article-title":"In vitro activity of imipenem\/relebactam against Pseudomonas aeruginosa isolated from patients with cystic fibrosis","volume":"67","author":"Ruiz","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijmmb.2026.101203_bib42","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.diagmicrobio.2015.04.012","article-title":"Microbiological activity of ceftolozane\/tazobactam, ceftazidime, meropenem, and piperacillin\/tazobactam against Pseudomonas aeruginosa isolated from children with cystic fibrosis","volume":"83","author":"Kuti","year":"2015","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijmmb.2026.101203_bib43","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jfma.2023.09.006","article-title":"Susceptibility of gram-negative isolates collected in Taiwan to imipenem\/relebactam and comparator agents\u2013SMART 2018\u20132021","volume":"123","author":"Wise","year":"2024","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.ijmmb.2026.101203_bib44","doi-asserted-by":"crossref","DOI":"10.1093\/jacamr\/dlae150","article-title":"Susceptibility of Gram-negative pathogens collected in Israel to ceftolozane\/tazobactam, imipenem\/relebactam and comparators: SMART 2018\u201322","volume":"6","author":"Wise","year":"2024","journal-title":"JAC Antimicrob Resist"},{"key":"10.1016\/j.ijmmb.2026.101203_bib45","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1093\/jac\/dkx136","article-title":"Activity of ceftolozane\/tazobactam against surveillance and \u2018problem'Enterobacteriaceae, Pseudomonas aeruginosa and non-fermenters from the British Isles","volume":"72","author":"Livermore","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijmmb.2026.101203_bib46","first-page":"474","volume":"11","author":"Giaccari","year":"2021"},{"key":"10.1016\/j.ijmmb.2026.101203_bib47","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2024.1347521","article-title":"Extensively drug-resistant Pseudomonas aeruginosa: clinical features and treatment with ceftazidime\/avibactam and ceftolozane\/tazobactam in a tertiary care university hospital center in Portugal\u2013A cross-sectional and retrospective observational study","volume":"15","author":"Mendes Pedro","year":"2024","journal-title":"Front Microbiol"},{"key":"10.1016\/j.ijmmb.2026.101203_bib48","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s13756-024-01459-5","article-title":"Molecular epidemiology, microbiological features and infection control strategies for carbapenem-resistant Acinetobacter baumannii in a German burn and plastic surgery center (2020\u20132022)","volume":"13","author":"Vital","year":"2024","journal-title":"Antimicrob Resist Infect Control"},{"key":"10.1016\/j.ijmmb.2026.101203_bib49","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1093\/jac\/dkae358","article-title":"Overall status of carbapenem resistance among clinical isolates of Acinetobacter baumannii: a systematic review and meta-analysis","volume":"79","author":"Ghahramani","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijmmb.2026.101203_bib50","series-title":"Antimicrobials in animal husbandry","first-page":"95","article-title":"Role of \u03b2-Lactams, \u03b2-Lactamases inhibitors, and efflux pump inhibitors in the battle against antibiotic resistance","author":"Marathe","year":"2026"}],"container-title":["Indian Journal of Medical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0255085726001611?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0255085726001611?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T08:21:46Z","timestamp":1789201306000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0255085726001611"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":48,"alternative-id":["S0255085726001611"],"URL":"https:\/\/doi.org\/10.1016\/j.ijmmb.2026.101203","relation":{},"ISSN":["0255-0857"],"issn-type":[{"value":"0255-0857","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rising threats of ceftolozane-tazobactam resistance in P. aeruginosa and A. baumannii: Species-, phenotype-, and geography-specific insights from a systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Indian Journal of Medical Microbiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijmmb.2026.101203","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Indian Association of Medical Microbiologists. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101203"}}